Research progress of severe analgesia and sedation on brain protection in patients with neurological severe conditions
LU Ming1 ZHANG Xuezhi1 LUO Taotao1 XIE Yongle2
1.The First Clinical Medical College of Gansu University of Chinese Medicine, Gansu Province, Lanzhou 730000, China;
2.Department of Intensive Care Medicine, the First People’s Hospital of Tianshui, Gansu Province, Tianshui 741000, China
Abstract：Traumatic brain injury (TBI) patients with pain, agitation and stress response lead to tachycardia, elevated blood pressure, and increased increased intracranial pressure, etc., increasing the risk of rebleeding, accidental injury, and death. Effective analgesia and sedation help control intracranial pressure and avoid violent fluctuations, especially during invasive procedures. Analgesic sedation can achieve brain protection. There is no definite plan of analgesia and sedation for patients with severe neurological diseases. How to rational analgesia and sedation is a problem faced by clinicians. This article reviewed the pathophysiological changes, the necessity of analgesia and sedation, the protective effects of commonly used analgesia and sedation drugs, and related debates, aiming to provide reference for the selection of analgesia and sedation programs for craniocerebral trauma.
卢铭1 张学芝1 罗涛涛1 颉永乐2. 重症镇痛镇静对神经重症患者脑保护研究进展[J]. 中国医药导报, 2023, 20(27): 51-54.
LU Ming1 ZHANG Xuezhi1 LUO Taotao1 XIE Yongle2. Research progress of severe analgesia and sedation on brain protection in patients with neurological severe conditions. 中国医药导报, 2023, 20(27): 51-54.
[1] Thapa K，Khan H，Singh TG，et al. Traumatic Brain Injury：Mechanistic Insight on Pathophysiology and Potential Therapeutic Targets [J]. J Mol Neurosci，2021，71（9）：1725-1742.
[2] Sulhan S，Lyon KA，Shapiro LA，et al. Neuroinflammation and Blood-brain Barrier Disruption Following Traumatic Brain Injury：Pathophysiology and Potential Therapeutic Targets [J]. J Neurosci Res，2020，98（1）：19-28.
[3] Ladak AA，Enam SA，Ibrahim MT. A Review of the Molecular Mechanisms of Traumatic Brain Injury [J]. World Neurosurgery，2019，131：126-132.
[4] Flanagan SR. Invited Commentary on “Centers for Disease Control and Prevention Report to Congress：Traumatic Brain Injury in the United States：Epidemiology and Rehabilitation” [J]. Arch Phys Med Rehabil，2015，96（10）：1753-1755.
[5] Wiener J，McIntyre A，Janzen S，et al. Opioids and Cerebral Physiology in the Acute Management of Traumatic Brain Injury：A Systematic Review [J]. Brain Inj，2019，33（5）：559- 566.
[6] Kaur P，Sharma S. Recent Advances in Pathophysiology of Traumatic Brain Injury [J]. Curr Neuropharmacol，2018，16（8）：1224-1238.
[7] Nikolian VC，Dekker SE，Bambakidis T，et al. Improvement of Blood-Brain Barrier Integrity in Traumatic Brain Injury and Hemorrhagic Shock Following Treatment With Valproic Acid and Fresh Frozen Plasma [J]. Crit Care Med，2018，46（1）：e59-e66.
[8] Michinaga S，Koyama Y. Pathophysiological Responses and Roles of Astrocytes in Traumatic Brain Injury [J]. Int J Mol Sci，2021，22（12）：6418.
[9] McGinn MJ，Povlishock JT. Pathophysiology of Traumatic Brain Injury [J]. Neurosurg Clin N Am，2016，27（4）：397-407.
[10] Cash A，Theus MH. Mechanisms of Blood-Brain Barrier Dysfunction in Traumatic Brain Injury [J]. Int J Mol Sci，2020， 21（9）：3344.
[11] Dixon KJ. Pathophysiology of Traumatic Brain Injury [J]. Phys Med Rehabil Clin N Am，2017，28（2）：215-225.
[12] Gao Y，Wang C，Jiang D，et al. New Insights into the Interplay between Autophagy and Oxidative and Endoplasmic Reticulum Stress in Neuronal Cell Death and Survival [J]. Front Cell Dev Biol，2022，10：994037.
[13] Zhao Z，Zhou Y，Tian Y，et al. Cellular Microparticles and Pathophysiology of Traumatic Brain Injury [J]. Protein Cell，2017，8（11）：801-810.
[14] O’Leary RA，Nichol AD. Pathophysiology of Severe Traumatic Brain Injury [J]. J Neurosurg Sci，2018，62（5）：542- 548.
[15] Meyfroidt G，Bouzat P，Casaer MP，et al. Management of Moderate to Severe Traumatic Brain Injury：An Update for the Intensivist published correction appears in Intensive Care Med [J]. Intensive Care Med，2022，48（6）：649-666.
[16] Davis JA，Grau JW. Protecting the Injured Central Nervous System：Do Anesthesia or Hypothermia Ameliorate Secondary Injury? [J]. Exp Neurol，2023，363：114349.
[17] Godoy DA，Badenes R，Pelosi P，et al. Ketamine in Acute Phase of Severe Traumatic Brain Injury “An Old Drug for New Uses?” [J]. Crit Care，2021，25（1）：19.
[18] Kayambankadzanja RK，Samwel R，Baker T. Pragmatic Sedation Strategies to Prevent Secondary Brain Injury in Low- resource Settings [J]. Anaesthesia，2022，77 Suppl 1：43-48.
[19] Kim S，Mortera M，Heyn PC，et al. An Overview of Systematic Reviews on the Pharmacological Randomized Controlled Trials for Reducing Intracranial Pressure after Traumatic Brain Injury [J]. Brain Inj，2022，36（7）：829-840.
[20] Schizodimos T，Soulountsi V，Iasonidou C，et al. An Overview of Management of Intracranial Hypertension in the Intensive Care Unit [J]. J Anesth，2020，34（5）：741-757.
[21] Payen JF，Schilte C，Bertrand B，et al. Toward Individualized Sedation in Patients with Acute Brain Damage published online ahead of print，2023 Mar 16 [J]. Anaesth Crit Care Pain Med，2023，42（4）：101219.
[22] Roberson SW，Patel MB，Dabrowski W，et al. Challenges of Delirium Management in Patients with Traumatic Brain Injury：From Pathophysiology to Clinical Practice [J]. Curr Neu- ropharmacol，2021，19（9）：1519-1544.
[23] Velle F，Lewén A，Howells T，et al. Temporal Effects of Barbiturate Coma on Intracranial Pressure and Compensatory Reserve in Children with Traumatic Brain Injury [J]. Acta Neurochir （Wien），2021，163（2）：489-498.
[24] Devlin JW，Skrobik Y，Gélinas C，et al. Clinical Practice Guidelines for the Prevention and Management of Pain，Agitation/Sedation，Delirium，Immobility，and Sleep Disruption in Adult Patients in the ICU [J]. Crit Care Med，2018， 46（9）：e825-e873.
[25] Starosta AJ，Adams RS，Marwitz JH，et al. Scoping Review of Opioid Use After Traumatic Brain Injury [J]. J Head Trauma Rehabil，2021，36（5）：310-327.
[26] Joshua W，Amanda M，Shannon J，et al. Opioids and Cerebral Physiology in the Acute Management of Traumatic Brain Injury：A Systematic Review [J]. Brain Injury，2019，33（5）： 559-566.
[27] Lu WB，Wang J. Remifentanil Alleviates Hypoxic-Ischemic Br- ain Damage-Induced Cognitive Impairment via BACH1 [J]. Neurosci Lett，2022，786：136802.
[28] Naldan ME，Taghizadehghalehjoughi A. Remifentanil Reduces Glutamate Toxicity in Rat Olfactory Bulb Neurons in Culture [J]. Braz J Anesthesiol，2021，71（4）：402-407.
[29] Engelhard K, Reeker W, Kochs E，et al. Effect of Remifentanil on Intracranial Pressure and Cerebral Blood Flow Velocity in Patients with Head Trauma [J]. Acta Anaesthesiol Scand，2004，48：396-399.
[30] Yang S，Zhao H，Wang H，et al. Comparison Between Remi - fentanil and Other Opioids in Adult Critically Ill Patients：A Systematic Review and Meta-Analysis [J]. Medicine （Baltimore），2021，100（38）：e27275.
[31] Garcia R，Salluh JIF，Andrade TR，et al. A Systematic Review and Meta-Analysis of Propofol Versus Midazolam Sedation in Adult Intensive Care （ICU） patients [J]. J Crit Care， 2021，64：91-99.
[32] Meyer S，Langer J，Poryo M，et al. Epileptic Status in a Pediatric Cohort （ESPED） Requiring Intensive Care Treatment：A Multicenter，National，Two-Year Prospective Survei- llance Study [published online ahead of print [J]. Epilepsia Open，2023，10.1002/epi4.12707.
[33] Sebastiani A，Bender S，Schafer MKE，et al. Posttraumatic Midazolam Administration Does Not Influence Brain Damage After Experimental Traumatic Brain Injury [J]. BMC Anesthesiol，2022，22（1）：60.
[34] Musick S，Alberico A. Neurologic Assessment of the Neurocritical Care Patient [J]. Front Neurol，2021；12：588989.
[35] Hausburg MA，Banton KL，Roman PE，et al. Effects of Propofol on Ischemia-Reperfusion and Traumatic Brain Injury [J]. J Crit Care，2020，56：281-287.
[36] Cui C，Zhang D，Sun K，et al. Propofol Maintains Th17/Treg Cell Balance and Reduces Inflammation in Rats with Traumatic Brain Injury Via the miR-145-3p/NFATc2/NF-κB Axis [J]. Int J Mol Med，2021，48（1）：135.
[37] Duclos C，Maschke C，Mahdid Y，et al. Brain Responses to Propofol in Advance of Recovery from Coma and Disorders of Consciousness：A Preliminary Study [J]. Am J Respir Crit Care Med，2022，205（2）：171-182.
[38] Hemphill S，McMenamin L，Bellamy MC，et al. Propofol Infusion Syndrome：A Structured Literature Review and Analysis of Published Case Reports [J]. Br J Anaesth，2019，122（4）：448-459.
[39] Chen J，Wang J，Li C，et al. Dexmedetomidine Reverses MTX-induced Neurotoxicity and Inflammation in Hippoc- ampal HT22 Cell Lines Via NCOA4-Mediated Ferritino- phagy [J]. Aging （Albany NY），2021，13（4）：6182-6193.
[40] Unchiti K，Leurcharusmee P，Samerchua A，et al. The Potential Role of Dexmedetomidine on Neuroprotection and Its Possible Mechanisms：Evidence from in Vitro and in Vivo Studies [J]. Eur J Neurosci，2021，54（9）：7006-7047.
[41] Tasbihgou SR，Barends CRM，Absalom AR. The Role of Dexmedetomidine in Neurosurgery [J]. Best Pract Res Clin Anaesthesiol，2021，35（2）：221-229.
[42] Zaal IJ，Devlin JW，Peelen LM，et al. A Systematic Review of Risk Factors for Delirium in the ICU [J]. Crit Care Med，2015，43（1）：40-47.
[43] Freyer N，Kn?觟spel F，Damm G，et al. Metabolism of Remimazolam in Primary Human Hepatocytes during Continuous Long-term Infusion in A 3-D Bioreactor System [J]. Drug Des Devel Ther，2019，13：1033-1047.
[44] Antonik LJ，Goldwater DR，Kilpatrick GJ，et al. A Placebo- and Midazolam-Controlled Phase Ⅰ Single Ascending-dose Study Evaluating the Safety，Pharmacokinetics，and Pharmacodynamics of Remimazolam （CNS 7056）：Part I. Safety，efficacy，and Basic Pharmacokinetics [J]. Anesth Analg，2012，115（2）：274-283.
[45] Wiltshire HR，Kilpatrick GJ，Tilbrook GS，et al. A Placebo- and Midazolam-Controlled Phase Ⅰ Single Ascending-dose Study Evaluating the Safety，Pharmacokinetics，and Pharmacodynamics of Remimazolam （CNS 7056）：Part II. Population Pharmacokinetic and Pharmacodynamic Modeling and Simulation [J]. Anesth Analg，2012，115（2）：284-296.
[46] Sato T，Nishiwaki K. Remimazolam Should Be Antagonized by An Adequate Flumazenil [J]. J Anesth，2023，37（1）：164- 165.
[47] Cornett EM，Novitch MB，Brunk AJ，et al. New Benzodiazepines for Sedation[J]. Best Pract Res Clin Anaesthesiol，2018，32（2）：149-164.
[48] 叶冲冲，谢永鹏，骆继业，等.不同剂量瑞马唑仑在ICU机械通气患者中的镇静效果及对血流动力学的影响[J].中国医药导报，2021，18（22）：121-124.
[49] Pantos MM，Kennedy DR，Nemec EC. Remimazolam：A Novel Option for Procedural Sedation in High-Risk Patients [J]. J Pharm Pract，2023，36（1）：149-154.
京公网安备 11010502046598号